Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

Safety and Efficacy of Inferior Vena Cava Reconstruction During Hepatic Resection.

Papamichail M, Marmagkiolis K, Pizanias M, Koutserimpas C, Heaton N.

Scand J Surg. 2019 Sep;108(3):194-200. doi: 10.1177/1457496918798213. Epub 2018 Sep 24.

PMID:
30249173
2.

Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.

Jackson DO, Trappey FA, Clifton GT, Vreeland TJ, Peace KM, Hale DF, Litton JK, Murray JL, Perez SA, Papamichail M, Mittendorf EA, Peoples GE.

Clin Immunol. 2018 Oct;195:28-35. doi: 10.1016/j.clim.2018.06.008. Epub 2018 Jul 17.

PMID:
30025819
3.

Congenital portosystemic venous shunt.

Papamichail M, Pizanias M, Heaton N.

Eur J Pediatr. 2018 Mar;177(3):285-294. doi: 10.1007/s00431-017-3058-x. Epub 2017 Dec 14. Review.

4.

Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.

Voutsas IF, Anastasopoulou EA, Tzonis P, Papamichail M, Perez SA, Baxevanis CN.

J Immunother Cancer. 2016 Nov 15;4:75. doi: 10.1186/s40425-016-0183-4. eCollection 2016.

5.

MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cells.

Anastasopoulou EA, Voutsas IF, Papamichail M, Baxevanis CN, Perez SA.

Oncoimmunology. 2016 May 2;5(7):e1178439. doi: 10.1080/2162402X.2016.1178439. eCollection 2016 Jul.

6.

Irreversible electroporation for the treatment of pancreatic neuroendocrine tumors.

Papamichail M, Ali A, Pizanias M, Peddu P, Karani J, Heaton N.

Korean J Hepatobiliary Pancreat Surg. 2016 Aug;20(3):116-20. doi: 10.14701/kjhbps.2016.20.3.116. Epub 2016 Aug 29.

7.

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.

Mittendorf EA, Ardavanis A, Litton JK, Shumway NM, Hale DF, Murray JL, Perez SA, Ponniah S, Baxevanis CN, Papamichail M, Peoples GE.

Oncotarget. 2016 Oct 4;7(40):66192-66201. doi: 10.18632/oncotarget.11751.

8.

Liver resection for the treatment of a congenital intrahepatic portosystemic venous shunt.

Papamichail M, Ali A, Quaglia A, Karani J, Heaton N.

Hepatobiliary Pancreat Dis Int. 2016 Jun;15(3):329-33. Review.

PMID:
27298112
9.

Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) procedure for hepatocellular carcinoma with chronic liver disease: a case report and review of literature.

Papamichail M, Pizanias M, Yip V, Prassas E, Prachalias A, Quaglia A, Peddu P, Heaton N, Srinivasan P.

Korean J Hepatobiliary Pancreat Surg. 2016 May;20(2):75-80. doi: 10.14701/kjhbps.2016.20.2.75. Epub 2016 May 11.

10.

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.

Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, Hale DF, Perez SA, Anastasopoulou EA, Pistamaltzian NF, Ponniah S, Baxevanis CN, von Hofe E, Papamichail M, Peoples GE.

Ann Oncol. 2016 Jul;27(7):1241-8. doi: 10.1093/annonc/mdw150. Epub 2016 Mar 30.

11.

A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.

Anastasopoulou EA, Voutsas IF, Keramitsoglou T, Gouttefangeas C, Kalbacher H, Thanos A, Papamichail M, Perez SA, Baxevanis CN.

Cancer Immunol Immunother. 2015 Sep;64(9):1123-36. doi: 10.1007/s00262-015-1717-1. Epub 2015 May 31.

PMID:
26026288
12.

Prostate cancer vaccines: the long road to clinical application.

Baxevanis CN, Papamichail M, Perez SA.

Cancer Immunol Immunother. 2015 Apr;64(4):401-8. doi: 10.1007/s00262-015-1667-7. Epub 2015 Feb 19. Review.

PMID:
25690791
13.

Immune biomarkers: how well do they serve prognosis in human cancers?

Baxevanis CN, Anastasopoulou EA, Voutsas IF, Papamichail M, Perez SA.

Expert Rev Mol Diagn. 2015 Jan;15(1):49-59. doi: 10.1586/14737159.2015.965684. Epub 2014 Oct 27. Review.

PMID:
25345403
14.

AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction.

Perez SA, Anastasopoulou EA, Papamichail M, Baxevanis CN.

Cancer Immunol Immunother. 2014 Nov;63(11):1141-50. doi: 10.1007/s00262-014-1582-3. Epub 2014 Jul 23.

PMID:
25052849
15.

IGF2BP1 expression in human mesenchymal stem cells significantly affects their proliferation and is under the epigenetic control of TET1/2 demethylases.

Mahaira LG, Katsara O, Pappou E, Iliopoulou EG, Fortis S, Antsaklis A, Fotinopoulos P, Baxevanis CN, Papamichail M, Perez SA.

Stem Cells Dev. 2014 Oct 15;23(20):2501-12. doi: 10.1089/scd.2013.0604. Epub 2014 Jul 14.

PMID:
24915579
16.

Invariant chain-peptide fusion vaccine using HER-2/neu.

Perez SA, Peoples GE, Papamichail M, Baxevanis CN.

Methods Mol Biol. 2014;1139:321-36. doi: 10.1007/978-1-4939-0345-0_26.

PMID:
24619690
17.

Immunologic biomarkers in prostate cancer: the AE37 paradigm.

Baxevanis CN, Papamichail M, Perez SA.

Hum Vaccin Immunother. 2014;10(5):1244-7. doi: 10.4161/hv.28032. Epub 2014 Feb 19.

18.

Therapeutic cancer vaccines: a long and winding road to success.

Baxevanis CN, Papamichail M, Perez SA.

Expert Rev Vaccines. 2014 Jan;13(1):131-44. doi: 10.1586/14760584.2014.852961. Review.

PMID:
24224539
19.

AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial.

Perez SA, Anastasopoulou EA, Tzonis P, Gouttefangeas C, Kalbacher H, Papamichail M, Baxevanis CN.

Cancer Immunol Immunother. 2013 Oct;62(10):1599-608. doi: 10.1007/s00262-013-1461-3. Epub 2013 Aug 10.

PMID:
23934022
20.

Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab.

Voutsas IF, Mahaira LG, Fotopoulou K, Kapranos N, Reclos JG, Gritzapis AD, Papamichail M, Perez SA, Baxevanis CN.

Int J Radiat Biol. 2013 May;89(5):319-25. doi: 10.3109/09553002.2013.765617. Epub 2013 Feb 1.

PMID:
23311575
21.

Immune classification of colorectal cancer patients: impressive but how complete?

Baxevanis CN, Papamichail M, Perez SA.

Expert Opin Biol Ther. 2013 Apr;13(4):517-26. doi: 10.1517/14712598.2013.751971. Epub 2013 Jan 6. Review.

PMID:
23289642
22.

Endogenous growth hormone and insulin after interposition of a reversed jejunal segment in short bowel syndrome. An experimental study on pigs.

Papamichail M, Digalakis M, Panagiotis P, Paisios O, Loti S, Sergentanis T.

BMC Res Notes. 2012 Aug 28;5:463. doi: 10.1186/1756-0500-5-463.

23.

Toxicity profiles of HER2/neu peptide anticancer vaccines: the picture from Phase/I and II clinical trials.

Baxevanis CN, Papamichail M, Perez SA.

Expert Rev Vaccines. 2012 Jun;11(6):637-40. doi: 10.1586/erv.12.33. No abstract available.

PMID:
22873121
24.

Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19-22, 2011: New perspectives in the immunotherapy of cancer.

Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Parisi G, Fonsatti E, Papamichail M, Parmiani G; NIBIT.

Cancer Immunol Immunother. 2012 Sep;61(9):1599-608. Epub 2012 Jun 27. No abstract available.

PMID:
22736255
25.

New insights into the role of NK cells in cancer immunotherapy.

Salagianni M, Baxevanis CN, Papamichail M, Perez SA.

Oncoimmunology. 2012 Mar 1;1(2):205-207.

26.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, HÃ¥kansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

27.

Developing effective cancer vaccines.

Baxevanis CN, Perez SA, Papamichail M.

Eur J Cancer. 2011 Sep;47 Suppl 3:S364-5. doi: 10.1016/S0959-8049(11)70205-2. Review. No abstract available.

PMID:
21944017
28.

AE37: a novel T-cell-eliciting vaccine for breast cancer.

Sears AK, Perez SA, Clifton GT, Benavides LC, Gates JD, Clive KS, Holmes JP, Shumway NM, Van Echo DC, Carmichael MG, Ponniah S, Baxevanis CN, Mittendorf EA, Papamichail M, Peoples GE.

Expert Opin Biol Ther. 2011 Nov;11(11):1543-50. doi: 10.1517/14712598.2011.616889. Epub 2011 Sep 6. Review.

PMID:
21895539
29.

Effect of the simultaneous administration of glucocorticoids and IL-15 on human NK cell phenotype, proliferation and function.

Moustaki A, Argyropoulos KV, Baxevanis CN, Papamichail M, Perez SA.

Cancer Immunol Immunother. 2011 Dec;60(12):1683-95. doi: 10.1007/s00262-011-1067-6. Epub 2011 Jun 26.

PMID:
21706285
30.

NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.

Salagianni M, Lekka E, Moustaki A, Iliopoulou EG, Baxevanis CN, Papamichail M, Perez SA.

J Immunol. 2011 Mar 15;186(6):3327-35. doi: 10.4049/jimmunol.1000652. Epub 2011 Feb 11.

31.

Effects of donor age, gender, and in vitro cellular aging on the phenotypic, functional, and molecular characteristics of mouse bone marrow-derived mesenchymal stem cells.

Katsara O, Mahaira LG, Iliopoulou EG, Moustaki A, Antsaklis A, Loutradis D, Stefanidis K, Baxevanis CN, Papamichail M, Perez SA.

Stem Cells Dev. 2011 Sep;20(9):1549-61. doi: 10.1089/scd.2010.0280. Epub 2011 Feb 15.

PMID:
21204633
32.

Massive Subcutaneus Emphysema following Endoscopic Retrograde Cholangiopancreatography with Sphincterotomy.

Papamichail M, Nikolaidis N, Anastasiou E, Sidirokastritis G, Prigouris P.

Case Rep Gastroenterol. 2010 Sep 20;4(3):399-403.

33.

Interposition of a reversed jejunal segment enhances intestinal adaptation in short bowel syndrome: an experimental study on pigs.

Digalakis M, Papamichail M, Glava C, Grammatoglou X, Sergentanis TN, Papalois A, Bramis J.

J Surg Res. 2011 Dec;171(2):551-7. doi: 10.1016/j.jss.2010.06.035. Epub 2010 Sep 8.

PMID:
20850774
34.

A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer.

Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M, Perez SA.

Cancer Immunol Immunother. 2010 Dec;59(12):1781-9. doi: 10.1007/s00262-010-0904-3. Epub 2010 Aug 12.

PMID:
20703455
35.

HER-2/neu as a target for cancer vaccines.

Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M.

Immunotherapy. 2010 Mar;2(2):213-26. doi: 10.2217/imt.09.89. Review.

PMID:
20635929
36.

Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.

Perez SA, Kallinteris NL, Bisias S, Tzonis PK, Georgakopoulou K, Varla-Leftherioti M, Papamichail M, Thanos A, von Hofe E, Baxevanis CN.

Clin Cancer Res. 2010 Jul 1;16(13):3495-506. doi: 10.1158/1078-0432.CCR-10-0085. Epub 2010 May 13.

37.

Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.

Gritzapis AD, Voutsas IF, Lekka E, Papamichail M, Baxevanis CN.

Cancer Res. 2010 Apr 1;70(7):2686-96. doi: 10.1158/0008-5472.CAN-09-2517. Epub 2010 Mar 16.

38.

A new era in anticancer peptide vaccines.

Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papamichail M, Baxevanis CN.

Cancer. 2010 May 1;116(9):2071-80. doi: 10.1002/cncr.24988. Review.

39.

Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy.

Lekka E, Gritzapis AD, Perez SA, Tsavaris N, Missitzis I, Mamalaki A, Papamichail M, Baxevanis CN.

Cancer Immunol Immunother. 2010 May;59(5):715-27. doi: 10.1007/s00262-009-0791-7. Epub 2009 Nov 11.

PMID:
19904532
40.

HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor properties.

Gritzapis AD, Fridman A, Perez SA, La Monica N, Papamichail M, Aurisicchio L, Baxevanis CN.

Vaccine. 2009 Dec 10;28(1):162-70. doi: 10.1016/j.vaccine.2009.09.104. Epub 2009 Sep 30.

PMID:
19799847
41.

Cancer immunotherapy.

Baxevanis CN, Perez SA, Papamichail M.

Crit Rev Clin Lab Sci. 2009;46(4):167-89. doi: 10.1080/10408360902937809. Review.

PMID:
19650714
42.

Mannose addition by yeast Pichia Pastoris on recombinant HER-2 protein inhibits recognition by the monoclonal antibody herceptin.

Vlahopoulos S, Gritzapis AD, Perez SA, Cacoullos N, Papamichail M, Baxevanis CN.

Vaccine. 2009 Jul 23;27(34):4704-8. doi: 10.1016/j.vaccine.2009.05.063. Epub 2009 Jun 9.

PMID:
19520203
43.

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.

Baxevanis CN, Perez SA, Papamichail M.

Cancer Immunol Immunother. 2009 Mar;58(3):317-24. doi: 10.1007/s00262-008-0576-4. Epub 2008 Aug 15. Review.

PMID:
18704409
44.

Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties.

Gritzapis AD, Voutsas IF, Lekka E, Tsavaris N, Missitzis I, Sotiropoulou P, Perez S, Papamichail M, Baxevanis CN.

J Immunol. 2008 Jul 1;181(1):146-54.

45.

Cancer immunotherapy: perspectives and prospects.

Perez SA, Papamichail M.

Adv Exp Med Biol. 2008;622:235-53. doi: 10.1007/978-0-387-68969-2_19. Review. No abstract available.

PMID:
18546632
46.

Clinical grade expansion of human bone marrow mesenchymal stem cells.

Sotiropoulou PA, Perez SA, Papamichail M.

Methods Mol Biol. 2007;407:245-63. doi: 10.1007/978-1-59745-536-7_17.

PMID:
18453260
47.

Immune properties of mesenchymal stem cells.

Sotiropoulou PA, Papamichail M.

Methods Mol Biol. 2007;407:225-43. doi: 10.1007/978-1-59745-536-7_16. Review.

PMID:
18453259
48.

Merkel cell carcinoma of the upper extremity: case report and an update.

Papamichail M, Nikolaidis I, Nikolaidis N, Glava C, Lentzas I, Marmagkiolis K, Karassavsa K, Digalakis M.

World J Surg Oncol. 2008 Mar 7;6:32. doi: 10.1186/1477-7819-6-32. Review.

49.

A novel quantitative flow cytometric method for measuring glucocorticoid receptor (GR) in cell lines: correlation with the biochemical determination of GR.

Voutsas IF, Gritzapis AD, Alexis MN, Katsanou ES, Perez S, Baxevanis CN, Papamichail M.

J Immunol Methods. 2007 Jul 31;324(1-2):110-9. Epub 2007 Jun 8.

PMID:
17582432
50.

CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients.

Perez SA, Karamouzis MV, Skarlos DV, Ardavanis A, Sotiriadou NN, Iliopoulou EG, Salagianni ML, Orphanos G, Baxevanis CN, Rigatos G, Papamichail M.

Clin Cancer Res. 2007 May 1;13(9):2714-21.

Supplemental Content

Loading ...
Support Center